KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Assets: 2017-2025

Historic Non-Current Assets for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $1.8 billion.

  • Amneal Pharmaceuticals' Non-Current Assets fell 9.56% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 9.56%. This contributed to the annual value of $1.9 billion for FY2024, which is 8.64% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Non-Current Assets stood at $1.8 billion, which was down 4.17% from $1.8 billion recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Non-Current Assets high stood at $2.5 billion for Q1 2022, and its period low was $1.8 billion during Q3 2025.
  • Over the past 3 years, Amneal Pharmaceuticals' median Non-Current Assets value was $2.0 billion (recorded in 2024), while the average stood at $2.0 billion.
  • Its Non-Current Assets has fluctuated over the past 5 years, first increased by 4.12% in 2022, then decreased by 12.70% in 2024.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Non-Current Assets stood at $2.4 billion in 2021, then fell by 1.32% to $2.4 billion in 2022, then fell by 12.26% to $2.1 billion in 2023, then dropped by 8.64% to $1.9 billion in 2024, then decreased by 9.56% to $1.8 billion in 2025.
  • Its Non-Current Assets stands at $1.8 billion for Q3 2025, versus $1.8 billion for Q2 2025 and $1.9 billion for Q1 2025.